T-cell acute lymphoblastic leukemia (T-ALL), a form of T-cell malignancy, is a typically
aggressive hematological malignancy with high rates of disease relapse and a poor …

Chimeric antigen receptor T-cell (CAR-T) therapy has been approved for relapsed/refractory
B-cell lymphomas and greatly improves disease outcomes. The impressive success has …

Current therapies for T-cell acute leukemia are based on risk stratification and have greatly
improved the survival rate for patients, but mortality rates remain high owing to relapsed …

Chimeric antigen receptor T cell (CAR-T) therapy has proven successful for B cell
lymphomas and leukaemias. This success has inspired the development of CAR-T for T cell …

T cell malignancies represent a diverse collection of leukemia/lymphoma conditions in
humans arising from aberrant T cells. Such malignancies are often associated with poor …

Hematologic malignancies, including leukemia, lymphoma, myeloproliferative disorder and
plasma cell neoplasia, are genetically heterogeneous and characterized by an uncontrolled …

抄録 T 細胞性腫瘍においては, B 細胞性腫瘍に対する CAR-T 細胞ではそれほど問題にならなかっ
た, T 細胞性腫瘍に対する CAR-T 細胞特有の問題がいくつかある. 一般に CAR-T …